Table 2.

Bone mineral density at baseline and after 1 year of antiepileptic drug treatment

	CBZ, n = 41	LTG, n = 23	PHT, n = 15	VPA, n = 14	ANOVA p*
Lumbar spine
Baseline, g/cm2†	1.016 ± 0.12	1.068 ± 0.11	1.073 ± 0.16	0.998 ± 0.15	0.21
1 Year, g/cm2†	1.021 ± 0.12	1.066 ± 0.09	1.077 ± 0.17	0.999 ± 0.16	0.25
Baseline Z score†	−0.20 ± 1.11	0.20 ± 0.84	0.19 ± 1.41	−0.35 ± 1.34
1-Year Z score†	−0.14 ± 1.09	0.26 ± 0.82	0.32 ± 1.53	−0.33 ± 1.43
Femoral neck
Baseline, g/cm2	0.792 ± 0.10	0.835 ± 0.11	0.871 ± 0.18	0.838 ± 0.18	0.21
1 Year, g/cm2	0.794 ± 0.10	0.828 ± 0.11	0.849 ± 0.16	0.843 ± 0.18	0.41
Baseline Z score	−0.51 ± 0.96	−0.17 ± 0.95	0.22 ± 1.46	−0.28 ± 1.60
1-Year Z score	−0.36 ± 0.89	−0.25 ± 1.08	0.07 ± 1.31	−0.12 ± 1.60
Total hip
Baseline, g/cm2	0.889 ± 0.12	0.922 ± 0.11	0.962 ± 0.15	0.926 ± 0.18	0.32
1 Year, g/cm2	0.892 ± 0.11	0.920 ± 0.11	0.961 ± 0.15	0.931 ± 0.19	0.39
Baseline Z score	−0.47 ± 0.97	−0.22 ± 0.89	0.14 ± 1.13	−0.23 ± 1.51
1-Year Z score	−0.47 ± 0.93	−0.25 ± 0.97	0.15 ± 1.12	−0.13 ± 1.60

^*p value of one-way analysis of variance (ANOVA) F test of main effect of antiepileptic drug group with 3,89 degrees of freedom for within-subject difference scores of 12-month change in bone mineral density.

^†Mean ± standard deviation.

CBZ = carbamazepine; LTG = lamotrigine; PHT = phenytoin; VPA = valproate.